EVO

Evotec SEB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$3.25

+65.8% vs current

Most likely

Base case

45%

Probability

Target price

$2.15

+9.7% vs current

B-

Bear case

35%

Probability

Target price

$1.25

-36.2% vs current

AI sentiment snapshot

Latest data as of 2026-07-16

AI commentary

News tone is strongly negative after the preliminary H1 update and guidance cut, while the reported post-print market reaction was sharply adverse. Analyst revisions are available but mixed: TD Cowen downgraded to Hold and cut its target to $2, while H.C. Wainwright retained Buy with a $4 target. Social, options, short-interest, and employee-sentiment coverage are unavailable; zeros indicate unavailable rather than neutral evidence. The thesis remains a low-conviction monitoring view pending the August 13 full results.

RankAlpha Sentiment Codex - 2026-07-16

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-07-31catalystPost-print repricing and guidance digestionHigh impact

The preliminary H1 release cut FY2026 revenue guidance to €570–610 million from €700–780 million and adjusted EBITDA guidance to a €70–105 million loss from breakeven-to-profit expectations. Market coverage reported a sharp immediate selloff, leaving further volatility risk despite much of the shock being priced in [#PR-2026-07-13].

2026-08-13eventFull H1 2026 results and outlook confirmationMedium impact

Evotec is scheduled to publish full second-quarter and first-half 2026 financial results on August 13, providing audited detail on preliminary revenue, EBITDA, liquidity, partnership timing, and cash costs [#PR-2026-07-13].

2027-03-31catalystBase-business conversion and Horizon savingsHigh impact

Underlying indicators are improving: D&PD net sales excluding strategic partnerships rose approximately 28% year over year in H1, while Just–Evotec Biologics reported high capacity utilization. Management expects increased commercial activity to convert into revenue from Q4 2026 onward and remains on track for 20–30% of Horizon savings in 2026, supporting a potential 2027 recovery [#PR-2026-07-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-16 • Updated nightlySource: Internal modelMethodology